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Summary 
The kappa-agonist behavioral effects of several ~unds 
were studied in rhesus monkeys and mice. Rhesus monkeys trained 
to discriminate ethylketazocine from saline responded as if 
ethylketazocine had been administered when given bridged oripa- 
vines with either N-allyl or N-cyclopropylmethyl, but not N- 
methyl, substituents. These compounds had Cv substitutions of 
either 2-hydroxy-2-pentyl or 2-hydroxy-5-methyl-2-hexyl. Monkeys 
also showed ethylketazocine-like responding when given U-50,488 
(trans-3,4-dichloro-N-methyl-N-[2- (l-pyrrolidinyl) cyclohexyl]- 
benzeneacetamide), a crmi0ound with an atypical structure not 
resembling any known narcotic. Additionally, ethylketazocine- 
like re~ponding was produced by two 5,9-alpha dimethyl 6-7-benzo- 
morphans with either an N-2-methoxyisobutyl or an N-2-methoxy- 
propyl substituent. The latter compound was the only compound 
active in producing ethylketazocine-like discriminative effects 
that also reversed morphine-withdrawal signs. The N-methyl 
bridged oripavines that were inactive in producing ethylketazo- 
cine-like discriminative effects reversed morphine withdrawal 
signs. 
Behavioral effects of narcotics have most clearly differentiated those 
presumed to be acting primarily on kappa receptors from those presumed to be 
acting primarily on mu receptors. For example, ethylketazocine neither 
suppresses nor precipitates a withdrawal syndrome in morphine-dependent dogs 
(i) and monkeys (2). Additionally, the direct agonist actions of 
ethylketazocine on behavior are clearly distinctive from those of morphine in 
the dog (1,3) as well as the monkey (2). Recent studies have shown 
drug-discrimination behavioral techniques in the rhesus monkey to differentiate 
quite effectively compounds with mu or kappa-agonist activity (4). For 
example, monkeys trained to make ~le response after etorphine administration 
and a different response after saline administration, respond as if ~y 
received etorphine after administration of several mu agonists, such as 
morphine, but respond as if saline were administered when given ethylketazocir~ 
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(5). Conversely, monkeys trained similarly, but with ethylketazocine rather 
than etorphine, respond as if given ethylketazocine after ackninistration of 
kappa agonists, such as ketazocine, but as if saline were administered when 
given mu agonists such as morphine (6). 
Most con~pounds previously identified as having kappa agonist activity have 
been of the benzomorphan structural class. We now report a compound with 
actions like ethylketazocine but structurally unrelated to known narcotics. 
Additionally, we report several bridged oripavines as well as two recently 
identified benzomorphans that have actions like ethylketazocine. 
MATER/ALS AND METHODS 
The subjects were experimentally naive rhesus monkeys maintained at about 
90% of their unrestricted feeding weights. During experimental sessions the 
subjects were restrained in primate chairs that were placed within isolation 
chambers facing a panel that contained stimulus lights, two response keys, and 
a receptacle into which food pellets could be dispensed. The subjects were 
trained with food reinforcement to make i00 consecutive responses on the left 
key following ethylketazocine (3.0 ug/kg) injection and I00 consecutive 
responses on the right key following saline injection. When responding was 
well trained and less than ten percent of the responses were on the 
inappropriate response key, testing of new drugs was initiated. During test 
sessions, 100 consecutive responses on either key produced food. Each drug was 
tested over a range of doses that were administered cumulatively within a 
single daily session. Ten minutes after each dose, stimulus lights in the 
chamber were illuminated and the subject could respond on either key until I00 
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Structures of conpounds studied in the present experiment 
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consecutive responses produced food or 3minutes elapsed. If a drug suppressed 
behavior to the extent that 3 minutes elapsed before completion of 100 
resTonses , the daily session was terminated. For more details of the training 
and testing procedures see (7). 
Rhesus monkeys maintained on morphine (3 mg/kg/6 hr) were occasionally 
withdrawn from morphine for 14 hours and single doses of drugs were tested for 
suppression or exacerbation of withdrawal signs according to procedures 
outlined by Deneau and Seevers (8) and Villarreal (9). 
Mmle mice vmighing about 20 g, bred in-house at NIH, were tested, eight 
per dose level, on a hot plate at 55 ° C. A mouse was considered a positive 
respondent if its tir~ to lift its hind paws was at least f~,e seconds greater 
than its longest reaction time when not drugged, over two consecutive trial 
periods. The number of positive respondents at each dose was used to determine 
the EDS0 by probit analysis. For details see (I0). 
The following drugs were used: ethylketazocine methane sulfonate 
(courtesy of Dr. W. M/chne, Sterling Winthrop) was dissolved in sterile water 
to which a small amount of lactic acid was added. The structures of other 
compounds ~e given in Figure i. The forms are as follows: ~4 715 - HCI, UM 
736 - base; UM 928 - HCI salt; UM 1246 - base; UM 1250 - P~r salt; []-50,488 - 
HCl (courtesy of Dr. P. yon Voigtlander, Upjohn); etorphine (UM 495) - HCI 
salt; ~-i 499 - HCI salt. All of the compounds except U-50,488 were 
(-)-isomers; U-50,488 ~ras the racenmte. 
PFSULTS AbD DISCUSSION 
All of ~he conloounds except the N-methyl analogues (etorphine and UM 499) 
produced ethylketazocine-like discriminative effects (Table i). There was 
little variation in potency among the four most potent compounds. The conloound 
with the most novel structure, U-50,488, was the least potent. ~?le active 
bridged oripavines are noteworthy in t/nat they had a very long duration of 
action. For example, suppression of behavior following 3.0 ug/kg of U~i 715 
lasted two days. 
TABLE 1 
Potencies of Narcotics Relative to Ethylketazocine (3.0 ug/kg) 
Rhesus Momkey Mouse 
EKC-Discriminative Sedative Analgesic 
Compound Effects Effects Effects 
UM 1250 1.7 5.9 22.5 
UM 715 1.0 i0.0 9.0 
UM 928 0.7 0.8 90.0 
UM 1246 0.6 0.5 0.2 
U~ 736 0.2 1.0 0.9 
U-50,488 0.01 0.1 0.02 
Etorphine IA* 40.0 187.5 
UM 499 IA 40.0 98.4 
*IA-Inactive up to doses (Etorphine: 3.0 ug/kg, UM 499:1.0 ug/kg) that 
suppressed responding 
The N-methyl analogues were quite potent in reversing withdrawal signs in 
morphine-dependent rhesus monkeys. Etorphine was 3000 times, and UM 499 1500 
times, was potent than morphine. Generally, the compounds that produced 
ethylketazocine-like discriminative effects did not suppress withdrawal signs in 
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the 14-hour withdrawn monkey. Rather, these cxmpounds produced a sedative 
effect that was characterized by ptosis, mydriasis, ataxia, and a decreased 
responsivity to stimuli from cage mates and human observers. The same sedative 
effects in normal subjects were typically antagonized by naloxone. There was 
more variation in potencies for producing sedative effects, and the rank order 
of these potencies was not the same as that for producing ethylketazocine-like 
discriminative effects. 
Three compounds, etorphine, UM 499 and UM 1250, both suppressed withdrawal 
and produced sedation. Etorphine and UM 499 produced sedation at doses greater 
than those that reversed withdrawal signs. In contrast, UM 1250 produced 
sedation at doses below those that reversed withdrawal signs. This compound is 
the only one that reversed withdrawal signs and produced ethylketazocine-like 
dJ scriminative effects. 
All of the drugs tested had analgesic effects in the hot plate test with 
mice. The most potent compound was etorphine and least potent U-50,488 which 
was also very short acting. Notable was UM 928, which was about equipotent to 
ethylketazocine in discriminative and sedative effects, but 90 times more 
potent in producing analgesia. Of the conpounds with ethylketazocine-like 
discriminative effects, UM 928 had the greatest separation of analgesic 
activity from the other actions. 
These novel conpounds with kappa-agonist actions have both practical and 
theoretical import. The long durations of action of the bridged oripavines can 
be exploited in studies of tolerance and dependence to kappa agonists. 
Previously identified kappa agonists have such short durations of action that 
it is difficult to maintain high enough tissue levels to confer a significant 
amount of tolerance. Additionally, the present data suggest that a previous 
supposition, that only compounds with a benzomorphan structure are kappa 
agonists (Chang et al., 1981), is incorrect. The variations in structures that 
are capable of acting as kappa agonists may help in elucidating more clearly 
structural requirements for kappa agonist activity. 
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